Freya Biosciences develops microbial immunotherapies that target immune dysregulation and inflammation associated with reproductive health conditions such as infertility, endometriosis, and preterm birth. By engineering live microbes to restore a healthy vaginal microbiome, the company aims to improve clinical outcomes for women undergoing IVF and those facing reproductive system disorders.
Funding
$49.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BMCVCSEA+3Founders
Product
Problem
Reproductive health conditions such as infertility, endometriosis, and preterm birth are often associated with immune dysregulation and inflammation stemming from an imbalanced vaginal microbiome (dysbiosis). Current treatments often fail to address the underlying dysbiosis, leading to limited efficacy or unsuitability for women trying to conceive. There is a need for therapies that can restore a healthy vaginal microbiome and modulate the immune response in the reproductive tract.
Solution
Freya Biosciences develops microbial immunotherapies designed to restore immune homeostasis and resolve inflammation linked to reproductive health disorders. Their lead asset, FB101, is an investigational live biotherapeutic product (LBP) administered vaginally to correct dysbiosis. By re-establishing a balanced vaginal microbiome, Freya's approach aims to improve outcomes for women undergoing IVF, struggling with endometriosis-related infertility, and at risk of preterm birth. The company employs a data-driven approach, integrating microbiome sequencing, proteomic/transcriptomic immune marker analysis, and clinical data to develop targeted therapeutic solutions.
Target Audience
The primary target audience includes women experiencing infertility, particularly those undergoing IVF or affected by endometriosis, as well as women at risk of preterm birth due to vaginal dysbiosis.
Features
- FB101: A vaginal microbial immunotherapeutic in Phase 1 clinical trials, designed to correct vaginal dysbiosis.
- Focus on restoring a balanced vaginal microbiome to modulate the immune system.
- Data-driven platform integrating microbiome (quantitative & whole genome sequencing), 450+ proteomic immune markers, 600+ transcriptomic immune markers, clinical outcomes & demographic data.
- Targeting reproductive system disorders including embryo implantation failure, infertility among women with endometriosis and preterm birth.
- Partnered with Boston IVF to conduct a prospective study among 300 women, investigating the microbiomes and corresponding immune profiles of women undergoing IVF.